Antibiotic Resistance of Helicobacter pylori in Nigeria

ANTIBIOTIC RESISTANCE OF HELICOBACTER PYLORI IN NIGERIA: TRENDS, CHALLENGES, AND BIOTECHNOLOGY-BASED SOLUTIONS (1999–PRESENT)

By: James Esther Orvini

 

TABLE OF CONTENTS

1 Abstract

2 Keywords

3 Introduction

4 Methods

 4.1 Study Design

 4.2 Literature Search Strategy

 4.3 Eligibility Criteria

 4.4 Study Selection and Data Extraction

 4.5 Data Analysis

5 Results

 5.1 Prevalence of H. pylori in Nigeria

 5.2 Antibiotic Susceptibility and Resistance Trends

 5.3 Diagnostic and Treatment Challenges

6 Discussion

 6.1 Drivers of Antibiotic Resistance in Nigeria

 6.2 Clinical and Public Health Implications

 6.3 Biotechnology-Based Solutions

7 Conclusion

8 References

 

1. ABSTRACT

Helicobacter pylori is a Gram-negative bacterium that colonizes the human stomach and is strongly associated with gastritis, peptic ulcer disease, and gastric cancer. In Nigeria, infection prevalence remains high, but treatment success is increasingly threatened by antibiotic resistance and limited diagnostic capacity. This review analyzes Nigerian studies from 1999 to the present to evaluate trends in prevalence, antibiotic susceptibility, treatment challenges, and biotechnology-based solutions.

Early data from Jos (Ani et al., 1999) showed high susceptibility of H. pylori to amoxicillin (100%), clarithromycin (87.3%), tetracycline (89%), and metronidazole (60%). Later evidence from Ile-Ife (Aboderin et al., 2007) demonstrated emerging multidrug resistance among clinical isolates. More recent Nigerian reviews indicate persistently high prevalence, often ranging between 70–90%, alongside increasing concerns about treatment failure caused by resistance and limited availability of culture-based susceptibility testing.

Available Nigerian evidence suggests a transition from high antibiotic susceptibility reported in earlier studies toward increasing resistance challenges documented in later investigations. Contributing factors include antibiotic misuse, self-medication, empirical treatment without susceptibility testing, and inadequate antimicrobial stewardship. This review highlights the importance of molecular diagnostics, antimicrobial surveillance systems, and biotechnology-driven approaches including PCR-based resistance detection, genomic sequencing, probiotics, and vaccine research.

 

2. KEYWORDS

Helicobacter pylori, antibiotic resistance, Nigeria, antimicrobial stewardship, biotechnology, molecular diagnostics

 

3. INTRODUCTION

Helicobacter pylori is a spiral-shaped, microaerophilic Gram-negative bacterium that infects more than half of the global population. It is a major cause of chronic gastritis and is strongly associated with peptic ulcer disease and gastric malignancies.

In developing countries such as Nigeria, infection rates remain high due to socioeconomic and environmental factors including overcrowding, sanitation challenges, and limited access to clean water. Studies conducted in different Nigerian regions have consistently reported high prevalence levels.

Treatment commonly involves proton pump inhibitors combined with antibiotics such as amoxicillin, clarithromycin, metronidazole, or tetracycline. However, eradication success depends greatly on local antibiotic resistance patterns.

Over recent decades, antibiotic resistance has become a major challenge affecting H. pylori treatment outcomes. This review evaluates Nigerian evidence from 1999 to the present to examine prevalence trends, resistance patterns, diagnostic limitations, and biotechnology-based solutions.

 

4. METHODS

 

4.1 Study Design

This study was conducted as a narrative literature review to evaluate the prevalence, antibiotic resistance patterns, diagnostic challenges, and biotechnology-based solutions associated with Helicobacter pylori infection in Nigeria from 1999 to the present.

 

4.2 Literature Search Strategy

A literature search was performed using electronic databases including PubMed, Google Scholar, and African Journals Online (AJOL). Search terms included:

“Helicobacter pylori Nigeria”

“H. pylori antibiotic resistance Nigeria”

“H. pylori antimicrobial susceptibility Nigeria”

“gastric infection Nigeria”

“molecular diagnosis of H. pylori”

“biotechnology approaches against antimicrobial resistance”

Boolean operators (AND, OR) were used to refine results.

 

4.3 Eligibility Criteria

Inclusion criteria:

Nigerian population studies

Studies reporting prevalence, resistance, diagnosis, or treatment outcomes

Peer-reviewed articles and scientific reports

Published from 1999 to present

English language publications

Exclusion criteria:

Non-Nigerian studies

Studies lacking relevant antimicrobial or prevalence data

Opinion articles and duplicates

 

4.4 Study Selection and Data Extraction

Studies were screened using titles, abstracts, and full-text review. Extracted data included:

Study location

Sample population

Diagnostic methods

Prevalence rates

Antibiotic susceptibility and resistance patterns

Treatment challenges

Proposed interventions

 

4.5 Data Analysis

A qualitative comparative analysis was performed to evaluate changes in infection burden, antibiotic susceptibility, emergence of resistance, diagnostic capacity, and biotechnology applications over time.

 

5. RESULTS

 

5.1 Prevalence of H. pylori in Nigeria

Across Nigeria, H. pylori infection remains highly prevalent.

Ani et al. (1999) investigated isolates from gastric patients in Jos.

Aboderin et al. (2007) reported a 73% infection rate among endoscopy patients in Ile-Ife.

Recent Nigerian reviews (2018–2022) report prevalence estimates between 70% and 90%.

These findings confirm persistent endemicity across regions and decades.

Table 1: Summary of Nigerian H. pylori Studies

Study

Location

Year

Major Findings

Ani et al.

Jos

1999

High susceptibility: Amoxicillin 100%, Clarithromycin 87.3%, Tetracycline 89%

Aboderin et al.

Ile-Ife

2007

73% prevalence; emergence of antibiotic resistance

Smith et al.

Nigeria (review)

2022

High prevalence with diagnostic and resistance challenges

 

5.2 Antibiotic Susceptibility and Resistance Trends

Early Nigerian studies showed strong antibiotic effectiveness:

Jos Study (1999):

Amoxicillin: 100% susceptibility

Tetracycline: 89%

Clarithromycin: 87.3%

Metronidazole: 60%

Later studies indicated increasing resistance concerns.

The Ile-Ife study (2007) reported multidrug-resistant H. pylori strains, including resistance to clarithromycin and metronidazole.

Recent evidence suggests reduced effectiveness of standard triple therapy and increasing treatment failure rates.

 

5.3 Diagnostic and Treatment Challenges

Key challenges include:

Limited access to culture and susceptibility testing

Reliance on empirical treatment

Poor antibiotic adherence

Lack of national resistance surveillance

Possible reinfection from oral and environmental sources

These factors contribute to persistent infection and treatment failure.

 

6. DISCUSSION

 

6.1 Drivers of Antibiotic Resistance in Nigeria

Major contributing factors include:

Antibiotic overuse

Self-medication

Incomplete treatment courses

Weak diagnostic infrastructure

Lack of routine susceptibility testing

These factors increase selection pressure favoring resistant strains.

 

6.2 Clinical and Public Health Implications

Increasing resistance may lead to:

Reduced eradication success

Higher risk of gastric ulcers and cancer

Increased healthcare costs

Need for alternative treatment strategies

 

6.3 Biotechnology-Based Solutions

1. Molecular Diagnostics

PCR-based methods enable rapid detection of H. pylori and resistance mutations.

2. Genomic Surveillance

Whole genome sequencing can track resistance evolution and transmission patterns.

3. Alternative Therapies

Probiotics for microbiome balance

Natural antimicrobial compounds

Bacteriophage-based approaches

4. Vaccine Development

Research into H. pylori vaccines may provide long-term prevention.

5. Strengthening Laboratory Systems

Improving biotechnology infrastructure in Nigeria will enhance diagnosis, surveillance, and treatment.

 

7. CONCLUSION

Helicobacter pylori remains highly prevalent in Nigeria, with increasing evidence of antibiotic resistance affecting treatment outcomes. Early studies showed strong susceptibility to key antibiotics, while later research demonstrates emerging resistance challenges.

Major barriers include weak diagnostic systems, antibiotic misuse, and limited surveillance. Biotechnology-based solutions such as molecular diagnostics, genomic monitoring, and alternative therapies are essential for future control.

This field integrates microbiology, genetics, and biotechnology, making it highly relevant for addressing infectious disease challenges in Nigeria and beyond.

 

8. REFERENCES (APA 7TH EDITION)

Ani, A. E., Malu, A. O., Onah, J. A., Queiroz, D. M. M., Kirschner, G., & Rocha, G. A. (1999). Antimicrobial susceptibility test of Helicobacter pylori isolated from Jos, Nigeria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 93(6), 659–661.

Aboderin, O. A., Abdu, A. R., Odetoyin, B. W., Okeke, I. N., Lawal, O. O., Ndububa, D. A., et al. (2007). Antibiotic resistance of Helicobacter pylori from patients in Ile-Ife, South-west Nigeria. African Health Sciences, 7(3), 143–147.

Smith, S. I., Ajayi, A., Jolaiya, T. F., & Essi

et, U. B. (2022). Prevalence, diagnosis and treatment of Helicobacter pylori infection in Nigeria. Nigerian Journal of Gastroenterology and Hepatology, 14(1), 2–10.